Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma

Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma

ObjectivePatients with hematological malignancies have an elevated risk of developing pneumonia after contracting COVID-19. Lymphoma is the most prevalent hematologic malignancy. It is critical to identify patients at high risk of contracting COVID-19-associated pneumonia.MethodsFrom January 11–31,...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dan Liu, Xia Yin, Hui Wang, Lijie Xing, Ping Li, Haichen Wei, Ji Ma, Qiang He, Linna Xie, Ke Lu, Zengjun Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Oncology
Subjects:	COVID-19 pneumonia lymphoma bruton’s tyrosine kinase inhibitor hematologic malignancy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1504809/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS
by: Michele Bibas, et al.
Published: (2024-06-01)

Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges
by: Sofija Kozarac, et al.
Published: (2025-01-01)

Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in patients with hematological malignancies from 2014 to 2022
by: Meng Li, et al.
Published: (2025-01-01)

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors
by: Russell J. Schilder, et al.
Published: (2025-03-01)

An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review
by: Shu-Cheng Wu, et al.
Published: (2024-01-01)

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
by: José Pinto-Fraga, et al.
Published: (2025-02-01)

Primary pulmonary diffuse large B cell lymphoma presenting with features of organizing pneumonia: a case report
by: Sunjie Li, et al.
Published: (2025-01-01)

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
by: Qingjian He, et al.
Published: (2025-01-01)

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01)

Ibrutinib-associated osteonecrosis of the jaw
by: Annu Singh, et al.
Published: (2024-03-01)

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
by: Tommaso Porcelli, et al.
Published: (2025-02-01)

Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial
by: Liu Y, et al.
Published: (2025-01-01)

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
by: Hu Jiaming, et al.
Published: (2025-01-01)

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality
by: Jain Nem Kumar, et al.
Published: (2024-03-01)

Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
by: Yukihiro Umeda, et al.
Published: (2025-01-01)

Vitiligo-like lesions following imatinib mesylate therapy: a case series and review of literature
by: Neerja Saraswat, et al.
Published: (2024-01-01)

Screening and identification of host signaling pathways for alleviating influenza-induced production of pro-inflammatory cytokines, IP-10, IL-8, and MCP-1, using a U937 cell-based influenza model
by: Si Chen, et al.
Published: (2025-01-01)

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01)

The effectiveness of exercise-based interventions on muscle mass, muscle strength, functional performance, aerobic capacity, and health-related quality of life in adults with malignant lymphoma undergoing chemotherapy: a systematic review of randomized controlled trials
by: Charlotte Groenset, et al.
Published: (2025-01-01)

RESULTS OF CLINICAL TRIALS OF MEDICAL TREA TMENT OF RENAL CELL CARCINOMA IN 2014–2015
by: A. M. Popov, et al.
Published: (2016-01-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations
by: Masato Kikuta, et al.
Published: (2025-01-01)

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
by: Cristina Maria Failla, et al.
Published: (2024-12-01)

A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022
by: TAN Meijuan, et al.
Published: (2024-07-01)

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
by: Nozomi Sasaki, et al.
Published: (2025-01-01)

Advanced breast cancer with pancreatic metastasis responding well to TKIs after ADC failure: Report of a rare case
by: Huiyun Lv, et al.
Published: (2025-02-01)

Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age
by: Mototsugu Oya, et al.
Published: (2025-01-01)

Assessment of efficacy and safety of imatinib as an adjunct host-targeted therapy for parasite clearance in chloroquine-resistant malaria: a prospective case control study
by: Fazeel Zubair Ahmed, et al.
Published: (2025-01-01)

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa
by: Rochelle Woudberg, et al.
Published: (2025-01-01)

Synchronous clonally related anaplastic large cell lymphoma and malignant histiocytosis
by: Mirvate Harb, et al.
Published: (2025-01-01)

Life-threatening Pneumocystis jiroveci Pneumonia with Cytomegalovirus Coinfection in a Follicular Lymphoma Patient During Rituximab-based Chemotherapy
by: Mu-Chun Yang, et al.
Published: (2024-01-01)

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients
by: Piyada Sitthideatphaiboon, et al.
Published: (2025-01-01)

Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India
by: Sangita A. Vanik, et al.
Published: (2023-07-01)

Efficacy and Safety of CART Cell Therapy in Aggressive B‐Cell Lymphomas Involving the Gastrointestinal Tract
by: Lixia Ma, et al.
Published: (2025-01-01)

Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
by: Jialin Qian, et al.
Published: (2025-03-01)

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
by: Kei Sonehara, et al.
Published: (2025-01-01)

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
by: Ugo Giordano, et al.
Published: (2025-01-01)

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy
by: Sara Cherradi, et al.
Published: (2025-01-01)

Solid lipid nanoparticles for increased oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia
by: Swagata Sinha, et al.
Published: (2024-12-01)

Primary giant ovarian diffuse large B-cell lymphoma
by: Maoyu Zhang, et al.
Published: (2025-02-01)